Explore.Target.Build.

What nature has kept secret for millions of years, we can now uncover in a single high-throughput experiment.

Our technology harnesses the power of genetics and AI to learn the biophysical parameters governing protein function.

Our team

André FaureCTO & co-founder

Engineer, computational biologist and coinventor of the ALLOX computational platform"passionate about working on truly disruptive technology at the intersection between AI and biology"

Victoria MalavéOperations & Administration Manager

Business Administration specialist with Human Resources experience in fast-paced industries"a great privilege to be part of the ALLOX family and support the team to push scientific boundaries"

Mireia SeumaLead Scientist

Biochemist and biotechnologist with extensive experience in high-throughput mutagenesis techniques"on a mission to innovate at ALLOX and scale up discovery of allosteric sites from tens to hundreds to thousands"

Ashraya RavikumarStructural Bioinformatics Scientist

Computational biologist with experience in machine learning, molecular modeling and protein structural bioinformatics"we're working on one of the most fascinating problems in drug discovery — allosteric regulation of proteins"

Lukas LimResearch Associate

Molecular Biologist devoted to automated synthetic biology"striving to simplify molecular biology tools to make protein targeting more rational"

Youssef MansourResearch Associate

Pharmacist turned protein scientist with a passion for macromolecular design"thrilled to be in a team leveraging interdisciplinary approaches to unlock the therapeutic potential of allosteric sites across diverse targets"

Júlia DomingoCEO & co-founder

Biologist, bioinformatician and coinventor of the ALLOX experimental platform“proud to realize the revolutionary potential of our technology and test the core thesis of our research in the clinic”

Andrei PapkouPlatform Bioinformatician

Computational biologist with experience in molecular evolution of proteins and machine learning"fascinated by what emerges when experimental and computational biology meet — driven by purpose to create new medicines"

Raphaëlle PalauResearch Associate

Bioengineer, specialized in molecular biology and microbiology"excited by the opportunity to work on innovative science that opens new avenues for drug discovery"

Emilio Erazo-FischerChief Business Officer

Neuroscientist, Operating Partner at Asabys Partners and former Director of Global BD&L at Boehringer Ingelheim"building stimulating relationships with pharma and biotech to maximize the transformative potential of our technology"

Ben LehnerChief Scientific Advisor & co-founder

Head of Generative and Synthetic Genomics, Wellcome Sanger Institute; ICREA Professor, CRG and Fellow of the Royal Society“we’re going beyond what we can do in academia and having a lot of fun at the same time”

Chloé GoujonPeople Representative

People & Culture expert with 10+ years of international experience; Passionate about bridging Talent Development and People Strategy across mission-driven startups"thrilled to support & empower a team doing science that could genuinely change patients' lives: when people thrive, the mission thrives"

Pablo BaezaChief Discovery Officer & co-founder

Computational biochemist, data scientist and deep mutagenesis guru“the coolest thing about what we’re doing is the potential it has to improve the lives of millions of patients”

Sol AdaglioSenior Research Associate

Biotechnologist specialized in molecular and microbiology"driven by the opportunity to apply my experience in biotechnology to research that has the potential to reshape healthcare"

Pilar CasadoChief Financial Officer

Business Administration graduate, former Deloitte auditor and La Perla EMEA CFO and Business Partner; 7+ years serving as CFO for biotech startups

Ahish SujayBioinformatics Pipeline Engineer

Bioinformatician with experience building and operating production bioinformatics pipelines"thrilled to be at the intersection of cutting-edge biology and computation, where the pipelines we build today could shape the drug targets of tomorrow"

We are a team of explorers and builders passionate about revolutionising drug discovery.

Boldness

Ingenuity

Determination

Teamwork

Openness

Fairness

Join us

At ALLOX the success of our revolutionary scientific approach is as important to us as our mission to create a healthy, honest and respectful culture, both internally and with our partners.

We believe that — as in other living systems — team robustness and evolvability are a consequence of diversity, and that individuals thrive when they’re empowered with freedom and responsibility.

If you’re excited about the prospect of working with us, get in touch!

News

Team Update: Raphaëlle Palau and Ahish Sujay join ALLOX

Two new team members at ALLOX, Raphaëlle in the lab and Ahish in the computational team

2026-08-06|NEWS

Team Update: New team member alert 𝘈𝘳𝘵𝘶𝘳𝘪𝘵𝘰 (R2D2 🤖 ) is joining the team

We are very excited to welcome a robot as a new lab team member

2026-07-31|NEWS

From Bottleneck to Benchmark: How we’re scaling Bioinformatics at ALLOX using the Seqera Platform (Nextflow)

As a computational team at ALLOX, we already had our ways of organizing pipelines and sharing data. We wondered: Do we really need another layer? Six months later, the answer is a resounding yes. We explain the three aspects that turned out to be game-changers.

2026-02-19|NEWS

Get in touch

For all enquiries, send us a message here or email us at hello@allox.bio. We look forward to hearing from you!

Name*

E-mail*

Content*

Investors

This company is capitalized by INNVIERTE, AN INVESTMENT PROGRAM OF CDTI, E.P.E.

Grants

Grant PTQ2023-013021 awarded by MCIU/AEI/10.13039/501100011033
Grant PTQ2024-013687 awarded by MCIU/AEI/10.13039/501100011033
Grant EXP-00177442 / SNEO-20251447 awarded by CDTI. ALLOSTERY EXPLORATION TECHNOLOGIES, S.L. BUSINESS PLAN. AI-enabled platform for the systematic discovery of allosteric drug targets and accelerate the development of innovative therapies for previously undruggable proteins. The project will validate this approach through the preclinical development of ALX-001, a selective allosteric inhibitor.

Parc Científic de Barcelona

C/Baldiri Reixac 4-8 (Torre R),

08028 Barcelona